All In Biotech

Drug Trial Radar · NCT00631033

DZX Mediated Insulin Suppression in Obese Men

Diazoxide-mediated Insulin Suppression in Hyperinsulinemic Obese Men, Part III

Last checked: Nov 20, 2026Latest source record: Nov 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Jul 2008

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Rijnstate HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 25 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether there is an additive effect of metformine on the weight reduction of obese hyperinsulinemic men who are treated with diazoxide.

Conditions

  • Obesity

Interventions

  • PlaceboDrug

  • DiazoxideDrug

  • Metformin + DiazoxideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rijnstate Hospital

    Arnhem, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.